keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy cardiotoxicity

keyword
https://www.readbyqxmd.com/read/29339701/subclinical-reduction-in-left-ventricular-function-using-triplane-and-2d-speckle-tracking-echocardiography-after-anthracycline-exposure-in-children
#1
Erman Çilsal, Ayşe Deniz Oğuz, Fatma Sedef Tunaoğlu, Serdar Kula, Ayhan Pektaş
OBJECTIVE: Speckle tracking echocardiography (STE) enables global and regional evaluation of the left ventricle (LV); therefore, it is the most useful method for detecting subclinical dysfunction in patients exposed to cardiotoxic agents. A novel technique triplane (3P) echocardiography also allows single beat assessment of LV global longitudinal strain values. We firstly aimed to demonstrate both two-dimensional (2D)- and 3PSTE-derived LV global longitudinal strain measurements in children after anthracycline exposure...
January 2018: Anatolian Journal of Cardiology
https://www.readbyqxmd.com/read/29329420/pyrrolidine-dithiocarbamate-reverses-bcl-xl-mediated-apoptotic-resistance-to-doxorubicin-by-inducing-paraptosis
#2
Seok Soon Park, Dong Min Lee, Jun Hee Lim, Dongjoo Lee, Sang Jun Park, Hwan Myung Kim, Seonghyang Sohn, Gyesoon Yoon, Young Woo Eom, Seong-Yun Jeong, Eun Kyung Choi, Kyeong Sook Choi
Elevated Bcl-xL expression in cancer cells contributes to DOX resistance, leading to failure in chemotherapy. In addition, the clinical use of high-dose doxorubicin (DOX) in cancer therapy has been limited by issues with cardiotoxicity and hepatotoxicity. Here, we show that co-treatment with pyrrolidine dithiocarbamate (PDTC) attenuates DOX-induced apoptosis in Chang-L liver cells and human hepatocytes, but overcomes DOX resistance in Bcl-xL-overexpressing Chang-L cells and several hepatocellular carcinoma (HCC) cell lines with high Bcl-xL expression...
January 10, 2018: Carcinogenesis
https://www.readbyqxmd.com/read/29321375/highly-potent-visnagin-derivatives-inhibit-cyp1-and-prevent-doxorubicin-cardiotoxicity
#3
Aarti Asnani, Bahoui Zheng, Yan Liu, You Wang, Howard H Chen, Anita Vohra, An Chi, Ivan Cornella-Taracido, Huijun Wang, Douglas G Johns, David E Sosnovik, Randall T Peterson
Anthracyclines such as doxorubicin are highly effective chemotherapy agents used to treat many common malignancies. However, their use is limited by cardiotoxicity. We previously identified visnagin as protecting against doxorubicin toxicity in cardiac but not tumor cells. In this study, we sought to develop more potent visnagin analogs in order to use these analogs as tools to clarify the mechanisms of visnagin-mediated cardioprotection. Structure-activity relationship studies were performed in a zebrafish model of doxorubicin cardiomyopathy...
January 11, 2018: JCI Insight
https://www.readbyqxmd.com/read/29316094/integrated-multifunctional-micelles-co-self-assembled-from-polypeptides-conjugated-with-natural-ferulic-acid-and-lipoic-acid-for-efficient-and-bioresponsive-doxorubicin-delivery
#4
Zhiyuan Zhong, Tao Chen, Min Qiu, Jian Zhang, Huanli Sun, Chao Deng
How to develop safe, easily accessible, and multifunctional nanocarriers is a big theme for nanomedicine research. Here, integrated multifunctional micelles (IMM) were developed by co-self-assembly of poly(ethylene glycol)-b-poly(L-lysine) derivatives with natural ferulic acid or lipoic acid. FA confers IMM with intrinsic antitumor activity, improved loading of doxorubicin (DOX) via π-π stacking, and reduced DOX cardiotoxicity. LA provides IMM with reversible crosslinking property which leads to a high colloidal stability with inhibited drug leakage and triggered intracellular DOX release...
January 9, 2018: Chemphyschem: a European Journal of Chemical Physics and Physical Chemistry
https://www.readbyqxmd.com/read/29315967/curcumin-ameliorates-doxorubicin-induced-cardiotoxicity-by-abrogation-of-inflammation-apoptosis-oxidative-dna-damage-and-protein-oxidation-in-rats
#5
Fulya Benzer, Fatih Mehmet Kandemir, Mustafa Ozkaraca, Sefa Kucukler, Cuneyt Caglayan
Doxorubicin (DXR) is a highly effective drug for chemotherapy. However, cardiotoxicity reduces its clinical utility in humans. The present study aimed to assess the ameliorative effect of curcumin against DXR-induced cardiotoxicity in rats. Rats were subjected to oral treatment of curcumin (100 and 200 mg/kg body weight) for 7 days. Cardiotoxicity was induced by single intraperitoneal injection of DXR (40 mg/kg body weight) on the 5th day and the rats sacrificed on 8th day. Curcumin ameliorated DXR-induced lipid peroxidation, glutathione depletion, decrease in antioxidant (superoxide dismutase, catalase, and glutathione peroxidase) enzyme activities, and cardiac toxicity markers (CK-MB, LDH, and cTn-I)...
January 5, 2018: Journal of Biochemical and Molecular Toxicology
https://www.readbyqxmd.com/read/29286579/systematic-review-of-pharmacogenomics-and-adverse-drug-reactions-in-paediatric-oncology-patients
#6
REVIEW
Rachel Conyers, Subalatha Devaraja, David Elliott
Many paediatric patients with cancer experience significant chemotherapy side effects. Predisposition to drug reactions is governed by single nucleotide polymorphisms (SNPs). We performed a systematic review of the literature from 2006 through 2016. Outcomes of interest included patient characteristics, cancer type drug of interest, genes investigated, toxicity identified and genetic polymorphisms implicated. The primary toxicities studied were neurotoxicity cardiotoxicity, osteonecrosis, and thromboembolism and hypersensitivity reactions...
December 29, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29284775/l-arginine-is-an-effective-medication-for-prevention-of-endothelial-dysfunction-a-predictor-of-anthracycline-cardiotoxicity-in-patients-with-acute-leukemia
#7
I Skrypnyk, G Maslova, T Lymanets, I Gusachenko
AIM: To evaluate the effectiveness of L-arginine in the prevention of endothelial dysfunction, which may be a predictor of anthracycline-induced myocardial injury, in patients with acute leukemia (AL) on the background of anthracycline antibiotics low cumulative doses from 100 to 200 mg/m2. MATERIALS AND METHODS: A total of 81 adult AL patients (38 males and 43 females with the age of 16-59 years) were studied. The patients were divided into two groups: group I (n = 34), AL patients treated with chemotherapy (CT) and L-arginine hydrochloride; group II (n = 47) - AL patients treated with CT only...
December 2017: Experimental Oncology
https://www.readbyqxmd.com/read/29277755/our-ace-in-the-hole-justifying-the-use-of-angiotensin-converting-enzyme-inhibitors-as-adjuvants-to-standard-chemotherapy
#8
REVIEW
Daniel P Radin, Austin Krebs, Arman Maqsudlu, Parth Patel
Angiotensin-I-converting enzyme (ACE) inhibitors have been very effective in treating cardiac hypertension since their clinical inception over four decades ago. Since then, it has been established that angiotensin II, the product of ACE, has oncogenic and pro-proliferative qualities, which begs the question as to whether ACE inhibitors may have oncolytic characteristics. In fact, scattered reports suggest that ACE inhibitors are oncolytic and oncopreventive, but the available literature has yet to be thoroughly examined...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29274027/chemotherapy-and-echocardiographic-indices-in-patients-with-non-hodgkin-lymphoma-the-onco-echo-study
#9
Katarzyna Mizia-Stec, Marek Elżbieciak, Maciej T Wybraniec, Monika Różewicz, Artur Bodys, Wojciech Braksator, Zbigniew Gąsior, Piotr Gościniak, Tomasz Hryniewiecki, Jarosław Kasprzak, Andrzej Wojtarowicz, Barbara Zdziarska, Edyta Płońska-Gościniak
The cardiotoxicity of chemotherapy (CTx) for non-Hodgkin's lymphomas is not well recognized. In order to facilitate individual risk counseling for patients, we analyzed the effect of CTx on echocardiographic indices in regard to clinical data in patients treated for non-Hodgkin's lymphoma (NHL). A prospective multicenter ONCO-ECHO trial included 67 patients with NHL (45 patients with DLBCL (diffuse large B cell lymphoma) and 22 with non-DLBCL). Patients received standard CTx, primarily R-CHOP, CHOP, R-COP and COP regimens...
December 22, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29245279/mitral-regurgitation-after-anthracycline-based-chemotherapy-in-an-adult-patient-with-breast-cancer-a-case-report
#10
Xiaoyan Liu, Yanlin Zhu, Xue Lin, Ligang Fang, Xiaowei Yan
RATIONALE: Anthracyclines cardiotoxicity characterized by dilated myocardiopathy has been well described in the literature. However, anthracyclines-induced valvular diseases have been seldom reported. PATIENT CONCERNS: In this study, we present the case of a 62-year-old Chinese female patient with breast cancer developing severe mitral regurgitation after anthracycline exposure. DIAGNOSES: The patient was diagnosed with mitral regurgitation with preserved left ventricular ejection fraction and normal cardiac chamber dimensions in the sixth month after the last course of anthracycline-containing chemotherapy...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29226596/state-of-the-art-review-chemotherapy-induced-cardiotoxicity-in-children
#11
REVIEW
Robert W Loar, Cory V Noel, Hari Tunuguntla, John L Colquitt, Ricardo H Pignatelli
Chemotherapy-induced cardiotoxicity in adults and children is a topic with a growing interest in the cardiology literature. The ability to detect cardiac dysfunction in a timely manner is essential in order to begin adequate treatment and prevent further deterioration. This article aims to provide a review on the myocardial injury process, chemotherapeutic agents that lead to cardiotoxicity, the definition of cardiotoxicity, and the methods of timely detection and treatment.
December 11, 2017: Congenital Heart Disease
https://www.readbyqxmd.com/read/29224368/immune-response-proteins-as-predictive-biomarkers-of-doxorubicin-induced-cardiotoxicity-in-breast-cancer-patients
#12
Li-Rong Yu, Zhijun Cao, Issam Makhoul, Jaclyn R Daniels, Suzanne Klimberg, Jeanne Y Wei, Jane Pf Bai, Jinong Li, Julia T Lathrop, Richard D Beger, Valentina K Todorova
Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5-10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment)...
January 1, 2017: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/29221219/the-paradox-of-the-first-cycle-of-chemotherapy-transient-improvement-of-contractility-and-diastolic-function-after-the-first-cycle-of-anthracycline-based-chemotherapy-a-prospective-clinical-trial
#13
Paweł Stachowiak, Andrzej Wojtarowicz, Marta Milchert-Leszczyńska, Krzysztof Safranow, Michał Falco, Robert Kaliszczak, Zdzisława Kornacewicz-Jach
Aims: Breast cancer is the most common cancer among women, and anthracyclines are the most commonly administered drugs for these patients. Cardiotoxicity is one of the complications, which limits the success of this therapy. Very few studies have evaluated anthracycline toxicities within the first few hours after the first infusion, and the majority of published studies were performed in animal models. The present study aimed to evaluate changes in echocardiographic parameters in women with breast cancer 24 hours after receiving the first dose of an anthracycline...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29217634/anthracycline-cardiotoxicity-an-update-on-mechanisms-monitoring-and-prevention
#14
REVIEW
Peter A Henriksen
Anthracycline chemotherapy causes dose-related cardiomyocyte injury and death leading to left ventricular dysfunction. Clinical heart failure may ensue in up to 5% of high-risk patients. Improved cancer survival together with better awareness of the late effects of cardiotoxicity has led to growing recognition of the need for surveillance of anthracycline-treated cancer survivors with early intervention to treat or prevent heart failure. The main mechanism of anthracycline cardiotoxicity is now thought to be through inhibition of topoisomerase 2β resulting in activation of cell death pathways and inhibition of mitochondrial biogenesis...
December 7, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29199719/retrospective-study-of-efficacy-and-safety-of-neoadjuvant-docetaxel-carboplatin-and-trastuzumab-in-her2-positive-locally-advanced-and-oligometastatic-breast-cancer-an-indian-experience
#15
A Tiwari, A Gogia, Svs Deo, N K Shukla, S Mathur, D N Sharma
BACKGROUND: The neoadjuvant chemotherapy in HER2-positive breast cancer consists of a chemotherapy backbone and HER2-directed therapy. The increase in cardiotoxicity by the use of trastuzumab with an anthracycline-based regimen has led to the use of nonanthracycline-based alternative regimens. The docetaxel, carboplatin, and trastuzumab (TCH) are one such regimen. The efficacy and toxicity of this regimen have not been widely studied in Indian patients. AIMS: This retrospective study aims to evaluate the efficacy and toxicity of neoadjuvant TCH regimen in locally advanced and oligometastatic HER2-positive breast cancer in Indian patients...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29198224/case-report-and-review-of-the-literature-the-utilisation-of-a-ventricular-assist-device-as-bridge-to-recovery-for-anthracycline-induced-ventricular-dysfunction
#16
Diane Krasnopero, Alfred Asante-Korang, Jeffrey Jacobs, Stacie Stapleton, Jennifer Carapellucci, Mathew Dotson, Gary Stapleton
Ventricular assist devices are used in children with heart failure as a bridge to myocardial recovery or cardiac transplantation. Anthracyclines cause cardiac toxicity and may result in acute or long-term cardiac failure. We describe the use of a ventricular assist device as a bridge to recovery in a child with severe acute anthracycline-induced cardiomyopathy, and we review the associated literature. A 6-year-old girl was treated for acute myeloblastic leukaemia with daunorubicin and mitoxantrone. After 2 weeks her final dose of chemotherapy, her Left Ventricular Ejection Fraction decreased to 21%...
December 4, 2017: Cardiology in the Young
https://www.readbyqxmd.com/read/29191785/folate-targeted-liposomal-nitrooxy-doxorubicin-an-effective-tool-against-p-glycoprotein-positive-and-folate-receptor-positive-tumors
#17
Elena Gazzano, Barbara Rolando, Konstantin Chegaev, Iris C Salaroglio, Joanna Kopecka, Isabella Pedrini, Simona Saponara, Matteo Sorge, Ilaria Buondonno, Barbara Stella, Alessandro Marengo, Massimo Valoti, Mara Brancaccio, Roberta Fruttero, Alberto Gasco, Silvia Arpicco, Chiara Riganti
Drug efflux transporters, in particular P-glycoprotein (Pgp), limit the success of chemotherapy. We previously found that synthetic doxorubicin conjugated with nitric oxide (NO)-releasing group overcomes resistance by inducing a NO-mediated inhibition of Pgp. Here we produced the first liposomal formulations of this nitrooxy-doxorubicin decorated with folic acid (FA), termed LNDF, in order to improve their active targeting against Pgp-expressing tumors. Folate was inserted onto liposomes surface using two different methods and the formulations were compared with respect to their technological features and in vitro behavior...
November 27, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29190004/long-term-safety-and-survival-outcomes-from-the-scandinavian-breast-group-2004-1-randomized-phase-ii-trial-of-tailored-dose-dense-adjuvant-chemotherapy-for-early-breast-cancer
#18
Alexios Matikas, Sara Margolin, Mats Hellström, Hemming Johansson, Nils-Olof Bengtsson, Lena Karlsson, Per Edlund, Per Karlsson, Elisabet Lidbrink, Barbro Linderholm, Henrik Lindman, Per Malmstrom, Kenneth Villman, Theodoros Foukakis, Jonas Bergh
PURPOSE: Although adjuvant polychemotherapy improves outcomes for early breast cancer, the significant variability in terms of pharmacokinetics results in differences in efficacy and both short and long-term toxicities. Retrospective studies support the use of dose tailoring according to the hematologic nadirs. METHODS: The SBG 2004-1 trial was a randomized feasibility phase II study which assessed tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A), the same regimen with fixed doses (group B) and the TAC regimen (group C)...
November 30, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29187460/adjuvant-breast-cancer-treatments-induce-changes-in-homoarginine-level-a-prospective-observational-study
#19
Hanna Aula, Tanja Skyttä, Suvi Tuohinen, Tiina Luukkaala, Mari Hämäläinen, Vesa Virtanen, Pekka Raatikainen, Eeva Moilanen, Pirkko-Liisa Kellokumpu-Lehtinen
AIM: To identify patients with breast cancer at risk for cardiotoxicity, we evaluated homoarginine (HA) behavior during adjuvant treatment. PATIENTS AND METHODS: Eighty-one patients received radiotherapy (RT) with or without endocrine treatment, and 19 received chemotherapy, RT and endocrine therapy. Serum HA, asymmetric dimethylarginine (ADMA) and high-sensitivity cardiac troponin T (hscTnT) were measured and echocardiography was performed before chemotherapy, and before and after RT...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29183892/treatment-of-advanced-colorectal-cancer-in-a-patient-with-cardiotoxic-reactions-to-5-fluorouracil-and-capecitabine-using-suboptimal-doses
#20
Joseph H Cioffi, Derek J Estes, Vaia Florou, Bach Ardalan
A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose. After careful considerations, the decision was made to attempt capecitabine retrial at a further suboptimal dose with combination chemotherapy where she no longer experienced cardiac events. As a result, the liver tumour shrank and rectal mass stabilised, tumour markers dropped and she underwent surgical resection of both masses...
November 27, 2017: BMJ Case Reports
keyword
keyword
4974
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"